Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Walgreen agrees to pay $35 million to settle allegations of improper medication switches for Medicaid beneficiaries

Walgreen has agreed to pay $35 million to settle allegations that the company improperly switched the form of generic medications prescribed to Medicaid beneficiaries to receive higher reimbursements from the program, the Hartford Courant reports (Levick, Hartford Courant, 6/5).

8 Jun 2008

Functional Electrical Stimulation may benefit people with Parkinson's

The use of electrical impulses to stimulate weak or paralyzed muscles, called Functional Electrical Stimulation (FES), is often used to help stroke or multiple sclerosis patients to walk.

2 Jun 2008

Timer genes control brain size

Experiments using fruit flies have helped a team at the MRC National Institute for Medical Research to identify genes that control how large the developing brain becomes.

29 May 2008

Avoiding spleen removal for Cooley's anemia sufferers

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent, and 20 out of every 100,000 African-Americans. The World Health Organization estimates that between 50,000-100,000 children are born with the disease each year.

27 May 2008

RNA toxicity contributes to neurodegenerative disease

Expanding on prior research performed at the University of Pennsylvania, Penn biologists have determined that faulty RNA, the blueprint that creates mutated, toxic proteins, contributes to a family of neurodegenerative disorders in humans.

27 May 2008

Yerkes researchers develop first transgenic nonhuman primate model of Huntington's disease

In the first study of its kind, researchers at the Yerkes National Primate Research Center, Emory University, in collaboration with researchers from the Department of Human Genetics at Emory's School of Medicine, have developed the first transgenic nonhuman primate model of Huntington's disease (HD), one of the most devastating human neurodegenerative diseases.

22 May 2008

RNA toxicity contributes to neurodegenerative disease

21 May 2008

Michael Parkinson becomes a 'dignity' ambassador for the elderly

An initiative by the British Government to encourage more respect for older people in care has been given added impact by the recruitment of TV talk show host Sir Michael Parkinson as a "dignity ambassador".

21 May 2008

Discovery of protein key to neuro-regeneration

Researchers at the Peninsula Medical School in the South West of England, University College London, the San Raffaele Scientific Institute in Milan and Cancer Research UK, have for the first time identified a protein that is key to the regeneration of damage in the peripheral nervous system and which could with further research lead to understanding diseases of our peripheral nervous systems and provide clues to methods of repairing damage in the central nervous system, according to a paper published this week in the Journal of Cell Biology.

20 May 2008

FDA approves first generic versions of Requip (ropinirole hydrochloride)

The U.S. Food and Drug Administration has approved the first generic versions of Requip (ropinirole hydrochloride) tablets for the treatment of moderate to severe Restless Legs Syndrome.

9 May 2008

New guidelines say botulinum toxin effective for many neurological disorders, but not headache

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating a variety of neurological conditions. Surprisingly, the drug may not be effective for chronic headaches, accrding to Allison Brashear, M.D., professor and chairman of the Department of Neurology at Wake Forest University Baptist Medical Center, who helped develop the guidelines.

9 May 2008

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.

6 May 2008

FDA needs additional $225 million, new authority to inspect foreign facilities to protect U.S. residents from unsafe prescription drug imports, agency officials say

FDA officials on Tuesday said the agency would need at least $225 million in additional funding annually, along with other authoritative powers, to adequately inspect the safety of imported drug products, the Baltimore Sun reports.

30 Apr 2008

Deep brain stimulation may help people with treatment resistant major depression

Researchers from the Cleveland Clinic, Brown University, and Massachusetts General Hospital will present results of a long-term outcome study that builds on previous promising research, which has shown that deep brain stimulation (DBS) is a potentially effective treatment option for people with treatment resistant major depression.

29 Apr 2008

Cell-based therapy shows promise in patients with Parkinson's disease

Rush University Medical Center neurosurgeon Dr. Roy A. E. Bakay and colleagues from Emory University, Atlanta found the therapy Spheramine was well-tolerated and patients experienced improvement in Parkinsonian symptoms (tremor, rigidity, slowness of movements, and impaired balance and coordination.)

28 Apr 2008

Scientists discover way to increase metabolism for weight loss

Scientists from Melbourne's Howard Florey Institute have discovered a way to aid weight loss and reduce the likelihood of developing diabetes by manipulating fat cells to increase the body's metabolism.

28 Apr 2008

Scientists explore brain's reaction to potent hallucinogen

Brain-imaging studies performed in animals at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory provide researchers with clues about why an increasingly popular recreational drug that causes hallucinations and motor-function impairment in humans is abused.

28 Apr 2008